meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
6
mUC - L1 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded